Villahermosa

Researchers are evaluating orforglipron to measure its effects on cardiovascular outcomes in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This phase 3 study aims to compare orforglipron with a placebo to better understand its impact on major cardiovascular events over about five years. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally along with standard care. The study is double-blinded, meaning neither participants nor researchers will know who receives the active drug or placebo during the trial period. During the study, participants will be followed for around five years, with researchers monitoring the time to the first major cardiovascular event and additional outcomes such as cardiovascular and kidney events, changes in kidney function measured by eGFR, and the onset of type 2 diabetes. The study includes regular assessments to track these outcomes and ensure participant safety throughout the long-term follow-up.

Researchers are studying children aged 6 to less than 12 years with asthma to compare the effects and safety of QMF149 a combination of indacaterol acetate and mometasone furoate with budesonide. This Phase 3, double-blind, randomized, two-period, crossover study aims to determine if QMF149 is superior to budesonide in improving lung function and asthma control in this pediatric population. Participants undergo a total study duration of up to 37 weeks, including screening and run-in periods, two 12-week treatment phases where they receive either QMF149 7540 mcg once daily or budesonide 200 mcg once daily via Breezhaler, separated by a 3-week washout period with fluticasone propionate. Following treatment periods, a 4-week safety follow-up occurs during which patients return to standard care. Throughout the study, children and their parentslegal guardians attend scheduled visits for assessments including lung function tests FEV1, asthma control questionnaires, peak expiratory flow rate measurements, and rescue medication use tracking. Safety is monitored by recording adverse events up to 30 days after the last dose. The study evaluates changes from baseline in lung function and asthma control after each treatment period, with participants supported in completing diaries and attending visits over the 37-week timeline.

Researchers are evaluating the effect of muvalaplin in lowering cardiovascular risks among adults with elevated lipoproteina who either have atherosclerotic cardiovascular disease or are at risk of a first heart attack or stroke. This phase 3, randomized, double-blind study aims to investigate whether muvalaplin can reduce major adverse cardiovascular events compared to placebo in this high-risk population. Participants are randomly assigned to receive either muvalaplin or a placebo, both given orally. The study is designed with parallel groups and will last about 5.25 years, during which the occurrence of cardiovascular events and changes in lipoproteina levels will be closely monitored. Throughout the study, participants will undergo regular assessments including measurement of lipoproteina levels, monitoring of cardiovascular events such as heart attacks or strokes, and evaluation of healthcare resource use. The primary outcome is the time to first major adverse cardiac event, tracked from baseline until the study ends. Safety and pharmacokinetics of muvalaplin will also be evaluated during the trial period.

Researchers are studying healthcare workers who have either received a COVID-19 vaccine or had a confirmed SARS-CoV-2 infection. This observational study involves multiple centers across eight countries and aims to analyze how different virus variants affect immunity from vaccination and natural infection. The focus is on understanding how virus variants may evade immune protection from vaccines or past infections by examining both antibody and cellular immunity. Participants include adult healthcare workers aged 18 and older who have known vaccination or infection history. The study follows each participant from their first immune event, either infection or vaccination, with follow-up planned for up to 24 months. Blood and serum samples are collected every four months and sent to central laboratories where advanced statistical and artificial intelligence methods analyze immune responses and viral sequences to assess protection and immune escape. Participants will provide retrospective and prospective data and biological samples over one to two years, depending on immune persistence. Researchers measure neutralizing antibodies, cellular immunity, and viral variants to understand immunity duration and effectiveness against different SARS-CoV-2 variants. The study tracks the number of healthcare workers involved through an average of three years and collects data to help define cross-immunity among variants and the impact of vaccine and natural infection combinations.

This research focuses on hospitalized adult patients diagnosed with COVID-19, aiming to understand how different SARS-CoV-2 variants and vaccination schedules affect the clinical outcomes of these patients. It is an observational multicenter study conducted across 12 clinics in 11 countries on 4 continents. The study also explores the impact of viral variants and vaccines on disease severity and treatment responses using biostatistical methods and artificial intelligence. Participants receive the standard care provided at their hospital while data and biological samples, such as blood and viral isolates, are collected for detailed analysis. The study includes both retrospective and prospective data collection from patients who tested positive for SARS-CoV-2 by PCR within 14 days before admission through hospital discharge. This observational study does not involve experimental treatments but monitors patients receiving usual care. Throughout the study, researchers collect clinical data on symptoms, interventions, and outcomes like mortality, ICU admissions, and mechanical ventilation use. They also track therapies such as renal replacement and blood transfusions. Data from biological samples support analysis of immune responses and viral characteristics. Participation involves data collection during hospitalization and follow-up over an average of four years to monitor severity and clinical outcomes related to COVID-19 and its variants.

Researchers are evaluating the use of local thermotherapy as a treatment to help control mild-to-moderate COVID-19, caused by the SARS-CoV-2 virus. This virus is a positive-sense single-stranded RNA virus responsible for a global pandemic with varying fatality rates. Raising the temperature on affected areas may inhibit viral replication by producing small interfering RNAs that block viral transcription. Thermotherapy has been previously used to target RNA viruses, cancer cells, and parasitic infections, which supports its potential use against COVID-19 to reduce viral load and aid the immune response. The study compares two groups one receiving usual hospital care plus an electric heat pad applied to the chest for 90 minutes twice daily over 5 days, and the other receiving usual hospital care alone. The heat pad raises the skin temperature to 40-42 0C, a range expected to facilitate virus elimination without causing discomfort. The electric cushion is a commercially available device widely used for muscle pain and arthritis treatment. Participants will undergo evaluations over 28 days to monitor disease progression and other health outcomes such as mortality, time to severe or critical COVID-19, hospitalization duration, oxygen requirement, and adverse events. Clinical status will be assessed using scales like the National Early Warning Score 2 NEWS-2, and safety and tolerance of the thermotherapy will be tracked. The trial is randomized and open-label, with follow-up visits occurring at multiple time points during and after the treatment period.

Researchers are investigating the long-term effects of COVID-19 by studying patients who have recovered from the acute phase of the disease to understand the prevalence and possible predictors of post COVID-19 condition. This condition involves symptoms that persist or newly appear at least three months after the initial infection, lasting for two or more months without another explanation. The study aims to identify factors such as age, gender, disease severity, and viral variants that may influence these ongoing symptoms and related organ damage. The study includes patients who have recovered from mild to severe COVID-19, with data collected retrospectively from post COVID-19 outpatient clinics and prospectively through ongoing follow-up visits. Patients undergo routine blood tests and evaluations by infectious disease specialists and other relevant medical professionals such as pulmonologists, cardiologists, neurologists, and psychologists, depending on individual clinical needs. Participants will be monitored over an average of three years to assess the incidence and persistence of post COVID-19 condition, identify risk factors, and evaluate long-term damage to organs including lungs, heart, and nervous systems. The study will also examine the role of different viral variants and immune responses. Data collection involves clinical visits, laboratory tests, and specialist assessments to provide a comprehensive understanding of post COVID-19 outcomes.